Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology

被引:92
作者
Dauden, E. [1 ]
Puig, L. [2 ]
Ferrandiz, C. [3 ]
Sanchez-Carazo, J. L. [4 ]
Hernanz-Hermosa, J. M. [5 ]
机构
[1] Hosp Univ Princesa, Dept Dermatol, IIS IP, Madrid, Spain
[2] Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
[3] Hosp Badalona Germans Trias & Pujol, Dept Dermatol, Barcelona, Spain
[4] Hosp Gen Univ Valencia, Dept Dermatol, Valencia, Spain
[5] Hosp Infanta Leonor, Dept Dermatol, Madrid, Spain
关键词
EVIDENCE-BASED RECOMMENDATIONS; FOUNDATION CLINICAL CONSENSUS; QUALITY-OF-LIFE; PLAQUE PSORIASIS; BIOLOGIC TREATMENT; OUTCOME MEASURES; EXPERT OPINION; S3; GUIDELINES; MANAGEMENT; TUBERCULOSIS;
D O I
10.1111/jdv.13542
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is a highly prevalent disease with a major impact on quality of life; therefore, appropriate patient management is mandatory. Given that many issues in psoriasis are controversial and not clearly defined by evidence-based medicine, management of psoriasis is very variable. Expert consensus can generate practical guidelines for optimization of patient care. Much has changed since 2009, when the Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis was published by the Spanish Psoriasis Group (GEP) of the Spanish Academy of Dermatology and Venereology (AEDV). The objective of the present consensus document is to provide the dermatologist with updated recommendations for the evaluation and treatment of patients with moderate-to-severe plaque psoriasis. All active members of the GEP of the AEDV were invited to participate in the survey. The final group comprised 46 members from various areas of Spain and with substantial experience in managing psoriasis. A 3-round Delphi process was used to reach consensus. Consistent agreement and consistent disagreement (consensus) required the achievement of at least two of the following three criteria: Criterion 1, which was based on the position occupied by the mean on a scale of 1-9 and an SD <2; Criterion 2, which was based on the median and interquartile range (IQR) on a scale of 1-9; Criterion 3, which considered the percentage of the voting experts on a scale of 1-9. The items studied were definition of severity, therapeutic objectives, indications for systemic treatment and biologic therapy, induction and maintenance periods, therapeutic failure, loss of response, relapse and rebound, continuous and intermittent therapy, screening of patients before treatment, adherence to therapy, follow-up of treatment outcome, combination of drugs, transitioning and associated comorbidities. Consistent agreement or disagreement (consensus) was achieved for 198 items (agreement, 3 criteria 146 items, 2 criteria 43 items; disagreement, 3 criteria 9 items, 2 criteria 0 items) based on the criteria described above. Completion of the Delphi consensus process enabled a broad and experienced group of Spanish psoriasis experts to provide useful and practical guidelines for the management and treatment of patients with moderate-to-severe psoriasis, particularly in areas where evidence is lacking.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 64 条
[1]   The diagnosis and treatment of early psoriatic arthritis [J].
Anandarajah, Allen P. ;
Ritchlin, Christopher T. .
NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (11) :634-641
[2]   Maximizing patient adherence for optimal outcomes in psoriasis [J].
Bewley, A. ;
Page, B. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 :9-14
[3]   Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study [J].
Boehncke, S. ;
Salgo, R. ;
Garbaraviciene, J. ;
Beschmann, H. ;
Hardt, K. ;
Diehl, S. ;
Fichtlscherer, S. ;
Thaci, D. ;
Boehncke, W. -H. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (10) :1187-1193
[4]   Co-morbidities in psoriasis vulgaris [J].
Boehncke, W. -H. ;
Buerger, C. ;
Boehncke, S. .
HAUTARZT, 2009, 60 (02) :116-121
[5]   Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus [J].
Boehncke, W-H ;
Brasie, R. A. ;
Barker, J. ;
Chimenti, S. ;
Dauden, E. ;
de Rie, M. ;
Dubertret, L. ;
Giannetti, A. ;
Katsambas, A. ;
Kragballe, K. ;
Naeyaert, J. M. ;
Ortonne, J-P ;
Peyri, J. ;
Prinz, J. C. ;
Saurat, J. H. ;
Strohal, R. ;
van de Kerkhof, P. ;
Sterry, W. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, 20 (08) :988-998
[6]   Critical review of generic and dermatology-specific health-related quality of life instruments [J].
Both, Hilde ;
Essink-Bot, Marie-Louise ;
Busschbach, Jan ;
Nijsten, Tamar .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (12) :2726-2739
[7]   What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature [J].
Bronsard, V. ;
Paul, C. ;
Prey, S. ;
Puzenat, E. ;
Gourraud, P-A ;
Aractingi, S. ;
Aubin, F. ;
Bagot, M. ;
Cribier, B. ;
Joly, P. ;
Jullien, D. ;
Le Maitre, M. ;
Richard-Lallemand, M-A ;
Ortonne, J-P .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 :17-22
[8]  
Cañete JD, 2014, ACTAS DERMO-SIFILOGR, V105, P216, DOI [10.1016/j.adengl.2013.07.003, 10.1016/j.ad.2013.07.001]
[9]  
Cansu DÜ, 2008, J RHEUMATOL, V35, P421
[10]   Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry [J].
Carrascosa, J. M. ;
Vilavella, M. ;
Garcia-Doval, I. ;
Carretero, G. ;
Vanaclocha, F. ;
Dauden, E. ;
Gomez-Garcia, F. J. ;
Herrera-Ceballos, E. ;
De la Cueva Dobao, P. ;
Belinchon, I. ;
Sanchez-Carazo, J. L. ;
Alsina, M. ;
Lopez-Estebaranz, J. L. ;
Ferran, M. ;
Peral, F. ;
Torrado, R. ;
Rivera, R. ;
Jimenez-Puya, R. ;
Mendiola, M. V. ;
Ferrandiz, C. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (07) :907-914